293 related articles for article (PubMed ID: 37013053)
1. Drugging IGF-1R in cancer: New insights and emerging opportunities.
Wang P; Mak VC; Cheung LW
Genes Dis; 2023 Jan; 10(1):199-211. PubMed ID: 37013053
[TBL] [Abstract][Full Text] [Related]
2. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
3. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.
Simpson A; Petnga W; Macaulay VM; Weyer-Czernilofsky U; Bogenrieder T
Target Oncol; 2017 Oct; 12(5):571-597. PubMed ID: 28815409
[TBL] [Abstract][Full Text] [Related]
4. Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine.
Lin SL; Lin CY; Lee W; Teng CF; Shyu WC; Jeng LB
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233084
[TBL] [Abstract][Full Text] [Related]
5. Targeting the insulin-like growth factor-1 receptor in human cancer.
Arcaro A
Front Pharmacol; 2013; 4():30. PubMed ID: 23525758
[TBL] [Abstract][Full Text] [Related]
6. Defining the pathway to insulin-like growth factor system targeting in cancer.
Rosenzweig SA; Atreya HS
Biochem Pharmacol; 2010 Oct; 80(8):1115-24. PubMed ID: 20599789
[TBL] [Abstract][Full Text] [Related]
7. IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.
Liefers-Visser JAL; Meijering RAM; Reyners AKL; van der Zee AGJ; de Jong S
Cancer Treat Rev; 2017 Nov; 60():90-99. PubMed ID: 28934637
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
9. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R targeting in cancer - does sub-cellular localization matter?
Soni UK; Jenny L; Hegde RS
J Exp Clin Cancer Res; 2023 Oct; 42(1):273. PubMed ID: 37858153
[TBL] [Abstract][Full Text] [Related]
11. Targeting IGF-1 signaling pathways in gynecologic malignancies.
Bruchim I; Werner H
Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
[TBL] [Abstract][Full Text] [Related]
12. Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King H; Aleksic T; Haluska P; Macaulay VM
Cancer Treat Rev; 2014 Oct; 40(9):1096-105. PubMed ID: 25123819
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
Rieder S; Michalski CW; Friess H; Kleeff J
Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
Garofalo C; Manara MC; Nicoletti G; Marino MT; Lollini PL; Astolfi A; Pandini G; López-Guerrero JA; Schaefer KL; Belfiore A; Picci P; Scotlandi K
Oncogene; 2011 Jun; 30(24):2730-40. PubMed ID: 21278796
[TBL] [Abstract][Full Text] [Related]
15. IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.
Foy KC; Miller MJ; Overholser J; Donnelly SM; Nahta R; Kaumaya PT
Oncoimmunology; 2014 Nov; 3(11):e956005. PubMed ID: 25941587
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
17. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
[TBL] [Abstract][Full Text] [Related]
18. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
19. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
20. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor.
Zhang H; Yee D
Expert Opin Investig Drugs; 2004 Dec; 13(12):1569-77. PubMed ID: 15566314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]